Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | SCD | O00767 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079969 | 0.90 | CYP3A4 (0.64) | CYP3A4CYP2D6SCD | |
| SCHEMBL14130994 | 0.86 | CYP3A4 (0.48) | CYP3A4CYP2D6 | |
| SCHEMBL4258724 | 0.84 | CYP3A4 (0.78) | CYP3A4CYP2D6SCD | |
| SCHEMBL3092360 | 0.84 | CYP3A4 (0.68) | CYP3A4CYP2D6SCD | |
| SCHEMBL3080676 | 0.84 | CYP3A4 (0.68) | CYP3A4CYP2D6SCD | |
| SCHEMBL3828435 | 0.83 | CYP3A4 (0.56) | CYP3A4CYP2D6SCD | |
| SCHEMBL3089821 | 0.83 | CYP3A4 (0.67) | CYP3A4CYP2D6SCD | |
| SCHEMBL4265024 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP2D6SCD | |
| SCHEMBL3828542 | 0.82 | SCD (0.56) | CYP3A4CYP2D6SCD | |
| SCHEMBL4257521 | 0.82 | SCD (0.81) | CYP3A4CYP2D6SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099755-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | SCD, SCD5, ACACA | CYP3A4 1882/4885CYP2D6 2182/4885SCD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.